Rebounding market share and strong pipeline may give Guidant hope
This article was originally published in Clinica
Executive Summary
It has not been the best of weeks for Guidant. On the same day that it announced it was taking Johnson & Johnson to court, the company reported a 60% slash in profits for the third quarter.